Clinical trials

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis
Danny Rischin, Nikhil I Khushalani, Chrysalyne D Schmults, Alexander Guminski, Anne Lynn S Chang, Karl D Lewis, Annette M Lim, Leonel Hernandez-Aya, Brett G M Hughes, Dirk Schadendorf, Axel Hauschild, Alesha A Thai, Elizabeth Stankevich, Jocelyn Booth, Suk-Young Yoo, Siyu Li, Zhen Chen, Emmanuel Okoye, Chieh-I Chen, Vera Mastey, Medha Sasane, Israel Lowy, Matthew G Fury, Michael R Migden

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e002757; DOI: 10.1136/jitc-2021-002757
Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)
Michael J Wagner, Megan Othus, Sandip P Patel, Chris Ryan, Ashish Sangal, Benjamin Powers, G Thomas Budd, Adrienne I Victor, Chung-Tsen Hsueh, Rashmi Chugh, Suresh Nair, Kirsten M Leu, Mark Agulnik, Elad Sharon, Edward Mayerson, Melissa Plets, Charles Blanke, Howard Streicher, Young Kwang Chae, Razelle Kurzrock

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e002990; DOI: 10.1136/jitc-2021-002990
Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers
Jarushka Naidoo, Karisa C Schreck, Wei Fu, Chen Hu, Alexander Carvajal-Gonzalez, Roisin M Connolly, Cesar A Santa-Maria, Evan J Lipson, Matthias Holdhoff, Patrick M Forde, Christopher Douville, Joanne Riemer, Amanda Barnes, Kristin J Redmond, Lawrence Kleinberg, Brandi Page, Nafi Aygun, Kenneth W Kinzler, Nickolas Papadopoulos, Chetan Bettegowda, Arun Venkatesan, Julie R Brahmer, Stuart A Grossman

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e002473; DOI: 10.1136/jitc-2021-002473
Intratumoral talimogene laherparepvec injection with concurrent preoperative radiation in patients with locally advanced soft-tissue sarcoma of the trunk and extremities: phase IB/II trial
Varun Monga, Benjamin J Miller, Munir Tanas, Sarag Boukhar, Bryan Allen, Carryn Anderson, Laura Stephens, Stacey Hartwig, Steven Varga, Jon Houtman, Lei Wang, Weizhou Zhang, Omar Jaber, Jon Thomason, David Kuehn, Maheen Rajput, Catherine Metz, K.D. Zamba, Sarah Mott, Chinemerem Abanonu, Sudershan Bhatia, Mohammed Milhem

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e003119; DOI: 10.1136/jitc-2021-003119
PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer
Alexander Stein, Donjete Simnica, Christoph Schultheiß, Rebekka Scholz, Joseph Tintelnot, Eray Gökkurt, Lisa von Wenserski, Edith Willscher, Lisa Paschold, Markus Sauer, Sylvie Lorenzen, Jorge Riera-Knorrenschild, Reinhard Depenbusch, Thomas J Ettrich, Steffen Dörfel, Salah-Eddin Al-Batran, Meinolf Karthaus, Uwe Pelzer, Lisa Waberer, Axel Hinke, Marcus Bauer, Chiara Massa, Barbara Seliger, Claudia Wickenhauser, Carsten Bokemeyer, Susanna Hegewisch-Becker, Mascha Binder

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002844; DOI: 10.1136/jitc-2021-002844
First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study
Sandra P D'Angelo, Celeste Lebbé, Laurent Mortier, Andrew S Brohl, Nicola Fazio, Jean-Jacques Grob, Natalie Prinzi, Glenn J Hanna, Jessica C Hassel, Felix Kiecker, Sara Georges, Barbara Ellers-Lenz, Parantu Shah, Gülseren Güzel, Paul Nghiem

Journal for ImmunoTherapy of Cancer Jul 2021, 9 (7) e002646; DOI: 10.1136/jitc-2021-002646
Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer
Lawrence G. Lum, Zaid Al-Kadhimi, Abhinav Deol, Vidya Kondadasula, Dana Schalk, Elyse Tomashewski, Patricia Steele, Kristie Fields, Melissa Giroux, Qin Liu, Lawrence Flaherty, Michael Simon, Archana Thakur

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002194; DOI: 10.1136/jitc-2020-002194
Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial
Yoland Antill, Peey-Sei Kok, Kristy Robledo, Sonia Yip, Michelle Cummins, Deborah Smith, Amanda Spurdle, Elizabeth Barnes, Yeh Chen Lee, Michael Friedlander, Sally Baron-Hay, Catherine Shannon, Jermaine Coward, Philip Beale, Geraldine Goss, Tarek Meniawy, Janine Lombard, John Andrews, Martin R Stockler, Linda Mileshkin

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002255; DOI: 10.1136/jitc-2020-002255
Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy
Abraham Nissani, Shaked Lev-Ari, Tomer Meirson, Elad Jacoby, Nethanel Asher, Guy Ben-Betzalel, Orit Itzhaki, Ronnie Shapira-Frommer, Jacob Schachter, Gal Markel, Michal J. Besser

Journal for ImmunoTherapy of Cancer May 2021, 9 (5) e001743; DOI: 10.1136/jitc-2020-001743
Pre-existing immune status associated with response to combination of sipuleucel-T and ipilimumab in patients with metastatic castration-resistant prostate cancer
Meenal Sinha, Li Zhang, Sumit Subudhi, Brandon Chen, Jaqueline Marquez, Eric V Liu, Kate Allaire, Alexander Cheung, Sharon Ng, Christopher Nguyen, Terence W Friedlander, Rahul Aggarwal, Matthew Spitzer, James P Allison, Eric J Small, Padmanee Sharma, Lawrence Fong

Journal for ImmunoTherapy of Cancer May 2021, 9 (5) e002254; DOI: 10.1136/jitc-2020-002254

Main menu

Clinical trials

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Clinical trials

Pages